Looks like a tough day ahead for shares of GILD, which are currently trading down about $22 from yesterday's close.The FDA has received a recommendation from an expert panel to deny approval of Gilead's experimental AIDS drug, Adefovir." The panel's 13-1 vote marks the first time an FDA panel has refused to back a drug for HIV. Panel members said the company hadn't proven the drug, called adefovir, to be potent enough to outweigh its known risk of triggering kidney damage. "TMF Jeanie
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Ma